 |
|
|
| |
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir,
Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic
HCV Genotype 1 Infection
|
| |
| |
Reported by Jules Levin
The 64th Annual Meeting of the AASLD
Washington, DC, November 1-5, 2013
Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hawkins T, Schwartz H, Rustgi V, Hinestrosa F, Levin JM, Younossi Z, Webster L, Eley T, Huang S-P, McPhee F, Grasela DM, Gardiner DF
Phase 3 Study: http://www.clinicaltrials.gov/ct2/show/NCT01973049?term=bms-791325&rank=2v
|
| |
|
|
|
|
|
